Butirosin A | 34291-02-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: Butirosin A
• 英文别名: butirosin B；butirosin A from Bacillus vitellinus；(2S)-4-amino-N-[(1R,2S,3R,4R,5S)-5-amino-4-[(2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-[(2S,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-2-hydroxycyclohexyl]-2-hydroxybutanamide
• CAS: 34291-02-6；34291-03-7；48235-24-1；48235-25-2；50507-50-1；51897-81-5；68422-65-1；70332-42-2
• 化学式: C₂₁H₄₁N₅O₁₂
• 分子量: 555.583
• InChiKey: XEQLFNPSYWZPOW-SVRMBHBBSA-N

物化性质

• 比旋光度：
  D25 +26° (c = 1.46 in water)
• 沸点：
  624.91°C (rough estimate)
• 密度：
  1.3764 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -7.3
• 重原子数：
  38
• 可旋转键数：
  10
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  312
• 氢给体数：
  12
• 氢受体数：
  16

安全信息

• 危险品标志：
  T
• 危险类别码：
  R61

制备方法与用途

类别：有毒物质

毒性分级：中毒

急性毒性：

• 腹腔注射-小鼠 LD50: 2198 毫克/公斤
• 静脉注射-小鼠 LD50: 580 毫克/公斤

可燃性危险特性：热分解排出有毒氮氧化物烟雾

储运特性：库房通风、低温干燥

灭火剂：水、干粉、二氧化碳、泡沫

反应信息

• 作为反应物：
  描述：

  Butirosin A 生成 Butirosin a 3'-phosphate
  参考文献：
  名称：

  HAKAXAMA, KADZUO;NOGAMI, IKUO;KITA, MAKOTO;KOMEHDA, MASAXIKO

  摘要：

  DOI：

文献信息

• [EN] ANIONIC CONJUGATES OF GLYCOSYLATED BACTERIAL METABOLITE<br/>[FR] CONJUGUÉS ANIONIQUES D'UN MÉTABOLITE BACTÉRIEN GLYCOSYLÉ
  申请人：GLYCAN BIOSCIENCES PTY LTD

  公开号：WO2010037179A1

  公开（公告）日：2010-04-08

  The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.

  该发明涉及与糖基化细菌代谢产物的阴离子结合物，可用于模拟被称为糖胺聚糖（GAGs）的阴离子生物活性分子的结构和/或活性。该发明还涉及制备这些结合物的过程。这些结合物在预防和/或治疗疾病条件方面具有用处，特别是慢性疾病条件，如炎症（包括过敏）疾病、转移性癌症和感染病原体（包括细菌、病毒或寄生虫）的情况。
• Novel aminoglycosides and uses thereof in the treatment of genetic disorders
  申请人：Bassov Timor

  公开号：US20090093418A1

  公开（公告）日：2009-04-09

  A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders.

  提供了一类新型的巴罗霉素衍生氨基糖苷类化合物，具有高效的终止密码子突变抑制活性、低毒性和高选择性作用于真核细胞。同时提供了制备这些巴罗霉素衍生氨基糖苷类化合物及其中间体的化学和化酶过程，以及含有它们的药物组合物，并在遗传疾病治疗中的应用。
• Aminoglycoside-polyamine displacers and methods of use in displacement chromatography
  申请人：Rege Kaushal

  公开号：US20070049741A1

  公开（公告）日：2007-03-01

  Aminoglycoside-polyamines are disclosed along with methods of use thereof in displacement chromatography and as DNA-binding ligands. The aminoglycoside-polyamines are derivatives of carbohydrates, such as sugars, amino sugars, deoxysugars, glycosides, nucleosides and their substituted counterparts. The subject polyamines possess a group in place of at least one hydrogen atom of at least one hydroxyl group of the carbohydrate compound. In these compounds R 1 is an alkyl group or an azaalkyl group, and R 2 is a primary or secondary amino group.

  本文披露了氨基糖苷-多胺以及它们在置换色谱和作为DNA结合配体中的使用方法。氨基糖苷-多胺是碳水化合物的衍生物，例如糖，氨基糖，去氧糖，糖苷，核苷和它们的取代物。这些多胺具有取代至少一种碳水化合物化合物的至少一个羟基的氨基团。在这些化合物中，R1是烷基或氮杂基，R2是一级或二级氨基。
• Epiminodeaminodeoxyaminoglycoside antibiotics and intermediates
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04020269A1

  公开（公告）日：1977-04-26

  Deoxyaminoglycoside antibiotics are prepared in a high yield from phosphorylated aminoglycosides by reacting a phosphorylated aminoglycoside (a) with a silylating agent, or (b) successively with (i) a silylating or acylating agent and (ii) a halogenating agent; then subjecting thus obtained intermediate to reduction. Deoxyaminoglycoside antibiotics are useful for treating infections caused by microorganisms which are resistant or non-resistant to the corresponding aminoglycoside antibiotics.

  脱氨基糖苷类抗生素是通过将磷酸化的氨基糖苷类化合物(a)与硅烷化试剂反应，或者(b)先后与(i)硅烷化或酰化试剂和(ii)卤代试剂反应，制备出高产率的。然后将得到的中间体还原。脱氨基糖苷类抗生素可用于治疗对应的氨基糖苷类抗生素耐药或非耐药微生物引起的感染。
• Dehydroxylation of aminosugars
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US04029883A1

  公开（公告）日：1977-06-14

  Dehydroxylation of aminoglycoside antibiotics is carried out by halogenation of phosphorylated aminoglycoside antibiotics followed by reduction of thus halogenated antibiotics. The dehydroxylation process is entirely new and gives the final product in a high yield. The resulting deoxyaminoglycoside antibiotics are effective against microorganisms including aminoglycoside antiobiotics-resistant microorganisms.

  氨基糖苷类抗生素的脱羟基化是通过磷酸化的氨基糖苷类抗生素的卤代作用，随后还原卤代抗生素完成的。这种脱羟化过程是全新的，可高产得到最终产品。所得的去氧氨基糖苷类抗生素对包括氨基糖苷类抗生素耐药微生物在内的微生物具有有效作用。